The University of Southampton
University of Southampton Institutional Repository

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial
Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial

The aim of palliative chemotherapy is to increase survival whilst maintaining maximum quality of life for the individual concerned. It is evident that the survival advantage offered by palliative chemotherapy for metastatic colorectal cancer has increased incrementally with the addition of each newly licensed therapeutic agent. More recently, advances in the field have led to the introduction of targeted monoclonal antibodies, whose benefits are documented in clinical trials and are acknowledged in their approval and licensing. Whilst we are continuing to explore the optimum use of the more traditional chemotherapy agents, with respect to both quantity and quality of life, these novel agents are battling to find their optimum place in the armamentarium. It is evident that a continuing add-one-in policy is likely to be detrimental to both patient and budget. Defining the positioning and duration of these combination therapies has become the subject of much debate and numerous current clinical trials. The Medical Research Council COIN trial is one of these trials, with a remit to explore further the optimum use of both standard agents and novel agents in the first-line setting for metastatic colorectal cancer.

Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Cetuximab, Clinical Trials as Topic, Colorectal Neoplasms, Neoplasm Metastasis, Palliative Care, Journal Article, Review
1473-7140
1237-45
Adams, Richard
3325b0a6-86f6-4ba4-a1ec-972b73083599
Meade, Angela
8b7678c2-d941-4c4b-abef-bbe15a574864
Wasan, Harpreet
52f35b3b-1dd6-4e96-993b-0f3d8f0db440
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Maughan, Tim
9f5b1ca4-9ed7-4100-bf04-c4026e4b5395
Adams, Richard
3325b0a6-86f6-4ba4-a1ec-972b73083599
Meade, Angela
8b7678c2-d941-4c4b-abef-bbe15a574864
Wasan, Harpreet
52f35b3b-1dd6-4e96-993b-0f3d8f0db440
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Maughan, Tim
9f5b1ca4-9ed7-4100-bf04-c4026e4b5395

Adams, Richard, Meade, Angela, Wasan, Harpreet, Griffiths, Gareth and Maughan, Tim (2008) Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial. Expert Review of Anticancer Therapy, 8 (8), 1237-45. (doi:10.1586/14737140.8.8.1237).

Record type: Article

Abstract

The aim of palliative chemotherapy is to increase survival whilst maintaining maximum quality of life for the individual concerned. It is evident that the survival advantage offered by palliative chemotherapy for metastatic colorectal cancer has increased incrementally with the addition of each newly licensed therapeutic agent. More recently, advances in the field have led to the introduction of targeted monoclonal antibodies, whose benefits are documented in clinical trials and are acknowledged in their approval and licensing. Whilst we are continuing to explore the optimum use of the more traditional chemotherapy agents, with respect to both quantity and quality of life, these novel agents are battling to find their optimum place in the armamentarium. It is evident that a continuing add-one-in policy is likely to be detrimental to both patient and budget. Defining the positioning and duration of these combination therapies has become the subject of much debate and numerous current clinical trials. The Medical Research Council COIN trial is one of these trials, with a remit to explore further the optimum use of both standard agents and novel agents in the first-line setting for metastatic colorectal cancer.

Full text not available from this repository.

More information

Published date: August 2008
Keywords: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Cetuximab, Clinical Trials as Topic, Colorectal Neoplasms, Neoplasm Metastasis, Palliative Care, Journal Article, Review
Organisations: Clinical Trials Unit

Identifiers

Local EPrints ID: 406329
URI: https://eprints.soton.ac.uk/id/eprint/406329
ISSN: 1473-7140
PURE UUID: 4ff7cb89-06a6-424a-bb99-c41e88a074ef
ORCID for Gareth Griffiths: ORCID iD orcid.org/0000-0002-9579-8021

Catalogue record

Date deposited: 10 Mar 2017 10:44
Last modified: 14 Mar 2019 01:33

Export record

Altmetrics

Contributors

Author: Richard Adams
Author: Angela Meade
Author: Harpreet Wasan
Author: Tim Maughan

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×